Anatara Lifesciences Ltd (ASX:ANR) CEO Steven Lydeamore was recently interviewed by Stockhead, for its "90 Seconds With" interview series. Steve provided an overview of the Company's key milestones for the next 12 months.
Regeneus Ltd (ASX:RGS) (Regeneus or the Company), a clinical-stage regenerative medicine company, releases its quarterly cashflow report and review of operational activities for the period ending 31 December 2019 (Q2 FY20).
Anatara Lifesciences Ltd (ASX:ANR) is pleased to provide a summary of the preclinical studies conducted to date for its Gastrointestinal ReProgramming (GaRP) dietary supplement as it targets commencement of a human clinical trial in 2Q 2020.
Anatara Lifesciences Ltd (ASX:ANR) is pleased to release its Appendix 4C for the quarter ending 31st December 2019. The Company's cash plus term deposits at the end of the quarter stood at $4.30m
Regeneus Ltd (ASX:RGS), a clinical-stage regenerative medicine company, has come to a mutual agreement with Japan-based manufacturer AGC Inc to terminate their exclusive manufacturing licence and joint venture agreement.
Anatara Lifesciences (ASX:ANR) is pleased to provide an update on the protocol for its clinical trial in irritable bowel syndrome (IBS) for its GaRP dietary supplement.
Anatara Lifesciences (ASX:ANR) is pleased to provide an update on its GaRP dietary supplement preclinical milestones, which is being developed to specifically target two human gastrointestinal disorders, inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS).
